Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Librera OncoLink / Repaso de Diarios
J. Lagergren and Others
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Reviewers: Kenneth Blank, MD
Source: The New England Journal of Medicine Volume 340, Number 11: March 18, 1999
Symptoms of gastroesophageal reflux (heartburn) may be related to the onsetof esophageal cancer. Heartburn is known to play an important role in thedevelopment of Barrett?s esophagus (a pre-cancerous condition of theesophagus), but little evidence exists linking reflux symptoms directly toesophageal cancer. A March 18th report in the New England Journal ofMedicine examines the relationship between heartburn and the risk ofesophageal cancer and cancer of the gastric cardia.
Tumors were carefully examined endoscopically and pathologically toclassify them properly as either gastric cardia cancers or esophagealcancers. Tumors that had their epicenters within two centimeters proximalor three centimeters distal to the gastroesophageal junction wereconsidered gastric cardia. The gastroesophageal junction was defined as thepoint where the proximal longitudinal mucosal folds begin in the stomach.
Professional interviewers using a computer assisted program obtained dataon reflux symptoms including heartburn and regurgitation. The interviewerswere not blinded to the patients diagnosis (case or control) but had noknowledge of the study hypothesis. To prevent collecting data on symptomscaused by the cancer, only symptoms that were present for at least fiveyears prior to study entry were included.
Reflux symptoms were associated with adenocarcinoma of the gastric cardia,but not as strongly as with esophageal adenocarcinoma. Symptoms were gradedby severity and frequency on a scale from 0-6.5, with higher scoresindicating worse and more frequent symptoms. Persons with high scores had anearly three fold increase in the risk of adenocarcinoma of the gastriccardia. Duration of symptoms also increased risk; persons with eitherheartburn or regurgitation greater than twenty years had a four foldincrease in the risk of gastric cardia adenocarcinoma.
Esophageal squamous cell carcinoma was not associated with heartburn orregurgitation regardless of the frequency, severity or duration ofsymptoms. Several confounding factors for esophageal cancer (adenocarcinomaand/or squamous carcinoma) were identified including Barrett?s esophagus,age, sex, body-mass index, smoking and alcohol use. However, none of theserisk factors significantly changed the risk estimates.
The clinical implications of this study are unclear. Should everyone withreflux symptoms be endoscoped to rule-out carcinoma? Since twenty percentof the adult population in the United States complains of heartburn weekly,such a policy would have a remarkably low yield and place a great burden ona medical system already strained financially. Instead, further studies arenecessary to define a group of patients with heartburn who are atsufficiently high risk of cancer that screening endoscopy is warranted.
Further studies are also necessary to determine the best treatment ofheartburn. Presently, many medications are effective at alleviating reflux symptoms including antacids, H2 blockers (cimetidine, ranitidine, famotidine, and nizatidine) andproton-pump inhibitors (such as lansoprazole and omeprazole).
However whether or not these medications will decrease the risk of canceris unknown. Clearly, heartburn is not a benign symptom and places patientsat risk for esophageal adenocarcinoma and gastric cardia adenocarcinoma.Patients with heartburn, and especially those with severe or long-standingsymptoms, should consult a physician for a complete evaluation.
Dr. Giantonio discusses the privileges bestowed on physicians in our society and the dangers of this. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

